An essential oil extract, derived from the rhizome of Curcuma wenyujin (CWE), possesses antioxidative, antimicrobial, and anti-inflammatory properties. However, it remains unknown how exactly CWE inhibits tumor growth. In this study, using human cervical cancer HeLa cells, the authors postulated that CWE has the ability to inhibit tumor growth. The study shows that CWE dose-dependently suppressed colony formation and inhibited the proliferation of HeLa cells through blockade of cell cycle progression at G1 phase and apoptosis. CWE-induced G1 arrest was associated with retinoblastoma protein dephosphorylation and reduced amounts of cyclins D1 and D3, and cyclin-dependent kinase 4 and 6 proteins. CWE treatment resulted in apoptosis in HeLa cells as evidenced by morphological changes, caspase activation and PARP cleavage, which can be reversed by a pan-caspase inhibitor. It was observed that CWE treatment activated the mitochondrial apoptotic pathway indicated by a decrease in Mcl-1 and Bcl-xL levels, resulting in mitochondrial membrane potential loss and caspases 9 activation. CWE-treated cells displayed reduced PTEN, AKT, and STAT3 phosphorylation and downregulation of NFκB signaling, providing a mechanism for the G1 arrest and apoptosis observed. Furthermore, CWE inhibited tumor growth of HeLa in a xenograft mouse tumor model, suggesting that CWE inhibited tumorigenesis by inhibiting cell proliferation and inducing apoptosis. These findings are the first to reveal the molecular basis for the anticervical cancer action of CWE. The results suggest that CWE could be developed as a drug for the management of cervical cancer.
Garcia MJA , Ward EM, Center MM, Hao Y., Siegel RL, Thun MJGlobal Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2.
Parkin DM, Bray F., Ferlay J., Pisani P.Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3.
Seow A., Koh WP, Chia KS, Shi L., Lee HP, Shanmugaratnam K.Trends in Cancer Incidence in Singapore 1968-2002. Singapore Cancer Registry Report No. 6, Singapore; 2004.
4.
Muñoz N., Bosch FX, de Sanjosé S., et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518-527.
5.
Castellsagué X., Diaz M., de Sanjosé S., et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention . J Natl Cancer Inst. 2006;98: 303-315.
6.
American Cancer Society.Cancer Facts & Figures 2006. Atlanta, GA: American Cancer Society; 2006.
7.
Chang H-M., But PPH, Yao S-C., Wang L-L., Yuen Sc-S.Pharmacology and Applications of Chinese Materia Medica. English ed. Singapore : World Scientific; 2001.
8.
Pharmacopoeia of the People’s Republic of China. Vol 1. 1st ed. Beijing, China: Chemistry Industry Press; 2005.
9.
Lai EY, Chyau CC, Mau JL, et al. Antimicrobial activity and cytotoxicity of the essential oil of Curcuma zedoaria. Am J Chin Med. 2004;32:281-290.
10.
Makabe H., Maru N., Kuwabara A., Kamo T., Hirota M.Anti-inflammatory sesquiterpenes from Curcuma zedoaria. Nat Prod Res. 2006;20:680-685.
11.
Tohda C., Nakayama N., Hatanaka F., Komatsu K.Comparison of anti-inflammatory activities of six curcuma rhizomes: a possible curcuminoid-independent pathway mediated by Curcuma phaeocaulis extract. Evid Based Complement Alternat Med. 2006;3:255-260.
12.
Park SD, Jung JH, Lee HW, et al. Zedoariae rhizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol. 2005;5:555-569.
13.
Xiao Y., Yang FQ, Li SP, Hu G., Lee SM, Wang YTEssential oil of Curcuma wenyujin induces apoptosis in human hepatoma cells . World J Gastroenterol. 2008;14:4309-4318.
14.
Syu WJ, Shen CC, Don MJ, Ou JC, Lee GH, Sun CMCytotoxicity of curcuminoids and some novel compounds from Curcuma zedoaria . J Nat Prod. 1998;61:1531-1534.
15.
Ky N., Lim CB, Li J., Tam JP, Hamza MS, Zhao Y.KLF4 suppresses HDACi induced caspase activation and the SAPK pathway by targeting p57(Kip2). Apoptosis. 2009;14:1095-1107.
16.
Lukas J., Bartkova J., Bartek J.Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint . Mol Cell Biol. 1996;16:6917-6925.
17.
Malumbres M. , Barbacid M.Cell cycle, CDKs and cancer: a changing paradigm . Nat Rev Cancer. 2009;9:153-166.
18.
Zhang Y., Fujita N., Tsuruo T.Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene. 1999;18:1131-1138.
19.
Garcia-Echeverria C., Sellers WRDrug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008; 27:5511-5526.
20.
Datta SR, Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
21.
del Peso L. , Gonzalez-Garcia M., Page C., Herrera R., Nunez G.Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science . 1997 ;278:687-689.
22.
Hennessy BT , Smith DL, Ram PT, Lu Y., Mills GBExploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov . 2005;4:988-1004.
23.
Frank DASTAT3 as a central mediator of neoplastic cellular transformation . Cancer Lett. 2007;251:199-210.
24.
Papa S., Bubici C., Zazzeroni F., et al. The NF-kappaBmediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 2006;13:712-729.
25.
Baeuerle PA , Baltimore D. I kappa B.: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242:540-546.
26.
Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U.Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation . Science. 1995;267:1485-1488.
27.
Yang FQ, Li SP, Chen Y., et al. Identification and quantitation of eleven sesquiterpenes in three species of Curcuma rhizomes by pressurized liquid extraction and gas chromatography- mass spectrometry. J Pharm Biomed Anal. 2005;39:552-558.
28.
Cao J., Qi M., Fang L., Zhou S., Fu R., Zhang P.Solid-phase microextraction-gas chromatographic-mass spectrometric analysis of volatile compounds from Curcuma wenyujin Y.H. Chen et C. Ling . J Pharm Biomed Anal. 2006;40:552-558.
29.
Sun XY, Zheng YP, Lin DH, Zhang H., Zhao F., Yuan CSPotential anti-cancer activities of furanodiene, a sesquiterpene from Curcuma wenyujin. Am J Chin Med. 2009;37:589-596.
30.
Ma E., Wang X., Li Y., et al. Induction of apoptosis by furanodiene in HL60 leukemia cells through activation of TNFR1 signaling pathway. Cancer Lett . 2008;271:158-166.
31.
Xiao Y., Yang FQ, Li SP, et al. Furanodiene induces G(2)/M cell cycle arrest and apoptosis through MAPK signaling and mitochondria-caspase pathway in human hepatocellular carcinoma cells. Cancer Biol Ther. 2007;6:1044-1050.
32.
Wang G., Li X., Huang F., et al. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death . Cell Mol Life Sci. 2005;62:881-893.
33.
Zhou H., Shen J., Hou J., Qiu Y., Luo Q.Experimental study on apoptosis induced by elemene in glioma cells . Chin J Cancer. 2003;22:959-963.
34.
Zhang HY, Hu CX, Liu CP, et al. Screening and analysis of bioactive compounds in traditional Chinese medicines using cell extract and gas chromatography-mass spectrometry . J Pharm Biomed Anal. 2007;43:151-157.
35.
Cory S., Adams JMThe Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-656.
36.
Buytaert E. , Callewaert G., Hendrickx N., et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericinmediated photodynamic therapy. FASEB J. 2006;20:756-758.
37.
Singh RP, Dhanalakshmi S., Agarwal R.Phytochemicals as cell cycle modulators: a less toxic approach in halting human cancers. Cell Cycle. 2002;1:156-161.
38.
Hunter T., Pines J.Cyclins and cancer: II. Cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-582.
39.
Lau WM, Ho TH, Hui KMp16INK4A-silencing augments DNA damage-induced apoptosis in cervical cancer cells. Oncogene. 2007;26:6050-6060.
40.
Lee SH, McCormick F.Downregulation of Skp2 and p27/ Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med. 2005 ;83:296-307.
41.
Hagemann T. , Bozanovic T., Hooper S., et al. Molecular profiling of cervical cancer progression. Br J Cancer. 2007;96:321-328.
42.
Yao TT, Dai YZ, Li SZExpression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma [in Chinese]. Ai Zheng . 2008;27:525-530.
43.
Kohrenhagen N., Voelker HU, Schmidt M., et al. Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008;34:293-300.
44.
Bertelsen BI , Steine SJ, Sandvei R., Molven A., Laerum ODMolecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation . Int J Cancer. 2006 ;118:1877-1883.
45.
Zhang XY, Zhang HY, Zhang PN, Lu X., Sun H.Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2008;139:237-244.
46.
Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene . 2000;19:2739-2744.
47.
Wen Z., Zhong Z., Darnell JE Jr.Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
48.
Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835-844.
49.
Fabbro D., Ruetz S., Bodis S., et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17-28.
50.
Polverino A. , Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006;66:8715-8721.
51.
Caldas-Lopes E., Cerchietti L., Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 ;106:8368-8373.
52.
Wilhelm SM, Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64:7099-7109.
53.
Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326-334.
54.
Chang YS, Adnane J., Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574.
55.
Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/ PRF/5 . Cancer Res. 2006;66:11851-11858.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
